Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01083316 · OUTCOME

Number of Participants Surviving at 5 Years

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis · Source last updated 2020-09-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
5 years

Analysis population: number of patients that completed at least one cycle of induction therapy

Groups in this outcome

Bortezomib and Dexamethasone

Induction: Bortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days Conditioning: Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4 Melphalan 70-100 mg/m2/day IV on days -2 and -1 Bortezomib: Induction: Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days Conditioning: Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4 Dexamethasone: Induction: Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days Melphalan: Conditioning: Melphalan 70-100 mg/m2/day IV on days -2 and -1

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bortezomib and Dexamethasone35

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bortezomib and Dexamethasone29Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        29
denoms
  1. counts
    1. group Id
      OG000
      value
      35
    units
    Participants
groups
  1. description
    Induction: Bortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days Conditioning: Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4 Melphalan 70-100 mg/m2/day IV on days -2 and -1 Bortezomib: Induction: Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days Conditioning: Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4 Dexamethasone: Induction: Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days Melphalan: Conditioning: Melphalan 70-100 mg/m2/day IV on days -2 and -1
    id
    OG000
    title
    Bortezomib and Dexamethasone
param Type
COUNT_OF_PARTICIPANTS
population Description
number of patients that completed at least one cycle of induction therapy
reporting Status
POSTED
time Frame
5 years
title
Number of Participants Surviving at 5 Years
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice